AngioDynamics to Hold Fiscal 2007 First Quarter Financial Results Conference Call on Monday, September 25, 2006.QUEENSBURY, N.Y. -- AngioDynamics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ANGO ANGO Algemene Nederlandse Gehandicapten Organisatie (Dutch: Equal Opportunities for Persons with Disabilities) ) today announced that the company will release fiscal 2007 first quarter results after the market closes on Monday, September 25, 2006. Eamonn P. Hobbs, president and chief executive officer, and Joseph G. Gerardi, chief financial officer, will host an investment community conference call beginning at 4:30 p.m. Eastern Time on September 25th to discuss these results and to answer questions. To participate in the live call by telephone, please dial (800) 435-1261 from the U.S., or for international callers, please dial (617) 614-4076. Please enter the passcode: 49465846. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of AngioDynamics' web site at http://investor.angiodynamics.com. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download, and install the necessary audio software. A replay will be available on the Web site. A telephone replay will be available from 6:30 p.m. Eastern Time on September 25, 2006 through 11:59 p.m. Eastern Time on October 2 by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international) and entering the passcode: 15827977. About AngioDynamics AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access vascular access Clinical medicine The ability to enter the vascular system; the ease with which the vascular system can be entered for administering therapy or obtaining blood for testing products, PTA PTA or parent-teacher association: see parent education. products, drainage products, thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. products, and venous products. More information is available at www.angiodynamics.com. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended June 3, 2006, may affect the actual results achieved by the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion